Related Experiment Video
Updated: Jun 18, 2026
05:51
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
Does clinical intolerance to a diagnostic acute levodopa challenge differentiate multiple system atrophy from PD?
Susana Estévez1, Santiago Perez-Lloret, Marcelo Merello
1Movement Disorders Section, Raúl Carrea Institute for Neurological Research (FLENI), Buenos Aires, Argentina.
The International Journal of Neuroscience
|November 18, 2009
Summary
Clinical intolerance symptoms during a levodopa challenge are not a reliable marker for diagnosing multiple system atrophy (MSA). This study found low specificity, indicating it
Area of Science:
- Neurology
- Neurodegenerative Diseases
- Clinical Diagnostics
Background:
- Diagnosing multiple system atrophy (MSA) presents significant clinical challenges.
- Accurate and timely diagnosis is crucial for patient management and prognosis.
Purpose of the Study:
- To evaluate the utility of clinical intolerance symptoms during an acute levodopa challenge as a diagnostic marker for MSA.
- To assess if symptoms like nausea, vomiting, hypotension, or perspiration predict MSA diagnosis.
Main Methods:
- Retrospective review of 507 dopaminergic acute challenge tests.
- Analysis of patients experiencing intolerance symptoms versus a control group matched for age, sex, and levodopa response.
- Final diagnoses of Parkinson's disease (PD) or MSA were based on established clinical criteria after follow-up.
Main Results:
- Of 507 tests, 23 patients (4.5%) reported intolerance symptoms.
- MSA was diagnosed in 4 of 23 (17%) patients with intolerance and 1 of 16 (6%) controls.
- Sensitivity for predicting MSA was 80%, but specificity was only 44%.
Conclusions:
- Clinical intolerance symptoms during acute levodopa challenge testing are not a reliable diagnostic indicator for MSA.
- Further research may be needed to identify more specific diagnostic markers for MSA.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...